Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination with azacitidine and venetoclax in AML.

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.